







a**b****c****mRassf1A promoter****d****e**

Supplementary Figure 1. Epigenetic regulation of RASSF1A and GATA factor binding upon ESC differentiation (a) Histone modifications on *RASSF1A*, *SOX2*, *GATA4* and *GAPDH* promoter CpG islands in H1 embryonic stem cells versus lymphoblastoid line GM12878 representing the mesodermal cell lineage. Transcription-activating epigenetic marks (H3K4me1;H3K4me2;H3K4me3;H3K9ac;H3K27ac) are found together with repressive marks (H3K9me3;H3K27me3) on the *RASSF1A* promoter in H1 cells, indicating its function as a bivalent promoter during pluripotency, switching to its fully active state upon differentiation. The *SOX2* promoter is only active during pluripotency, whereas the *GATA4* promoter remains silent and the *GAPDH* promoter is constitutively active. The analysis was performed using data from the ENCODE Project database (b) Experimental controls in ESC demonstrating pluripotency marker expression in the presence and absence of LIF (c) GATA binding sites located upstream of the mouse *Rassf1A* promoter (d) Western blot demonstrating that GATA1 overexpression induces *Rassf1A* endogenous levels in the presence of LIF, whereas *Gata1* KD reverses the phenotype even in the absence of LIF (e) Histone marks in siNT versus *Gata1*-depleted ES cells. * $P < 0.05$ of Student's t-test. Error bars indicate s.e.m. Data shown are representative of at least 3 independent experiments.



Supplementary Figure 2. RASSF1A regulates the ESC core pluripotency network (a)

Representative fluorescent images of Nanog and zsRASSF1A (zsR1A)-expressing ESC.

(b) Representative images and total cell numbers per condition 24 h post-transfection

with the indicated constructs. Control: zsCtrl, zsR1A: zsRASSF1A **(c)** Quantification of

Nanog-positive cells in the indicated conditions **(d)** RASSF1A reduces core stem cell

markers at the mRNA and **(e)** protein level **(f)** Representative images and total cell

numbers per condition 24 h post-transfection with control or RASSF1A-targeting








siRNAs. qPCR demonstrating RASSF1A KD **(g)** Upregulation of Nanog using an

alternative siRNA to Rassf1A minimises the possibility of off-target effects. Scale: 10-

50 μm , $*P<0.05$, $**P<0.01$ and $***P<0.001$, respectively, of Student's t-test. Error

bars indicate s.e.m. Data shown are representative of at least 3 independent

experiments.

a**b****c****d****e****f****g**

Supplementary Figure 3. RASSF1A-driven YAP complexes are transcriptional

regulators (a) Average profile of ChIP enrichment signal in genes differentially expressed upon RASSF1A knockdown. Relative enrichment of YAP binding sites in proximal and distal regions of the differentially expressed genes over the background (whole genome). TSS:Transcription Start Site, TTS:Transcription Termination Site **(b)**

Technical controls for YAP ChIP-seq. Total sheared chromatin inputs from the indicated conditions depicting equal occupancy of classical YAP- β -catenin target genes **(c)** Volcano plot of the Flag-YAP interactome in ESC in response to RASSF1A

loss. All mass-spec intensities were normalized to YAP intensities for each sample to ensure equal loading. See also Supplementary Data 3. In the absence of RASSF1A, YAP-TEAD and YAP-TCF3 complexes are stabilised **(d)** elution volumes and absorbance


traces from gel filtration column of ESC lysates. Fractions selected for main figure size exclusion figures indicated with red bar and elution fraction of molecular weight markers (top) **(e)** Western blotting of YAP immunoprecipitates using an additional

siRNA to RASSF1A, identifying a different region of the target sequence (siRassf1A #2). qPCR showing the efficiency of siRassf1A #2 **(f)** Western blotting of Yap immunoprecipitates in shGFP and shRassf1A-expressing ESC lines, validating

increased association of YAP with both TEAD2 and β -catenin upon RASSF1A loss. Bar graphs represent quantification of the TEAD2 and β -catenin relative ratio to YAP **(g)**

Western blotting of TEAD2 immunoprecipitates and totals from ESC with the indicated antibodies. YAP is required for TEAD2- β -catenin complex formation. $*P<0.05$ and $**P<0.01$, respectively, of Student's t-test. Error bars indicate s.e.m.

Data shown are representative of at least 3 independent experiments.



Supplementary Figure 4. RASSF1A loss-mediated effects require intact YAP, TEAD2

and β -catenin (a) Control for the generation of stable shRASSF1A-expressing ESC

lines **(b)** Western blotting demonstrating efficient siRNA-mediated silencing of β -

catenin, TCF7L1(TCF3) and TCF7L2 (TCF4) in ESC, corresponding to Fig. 3g and

Supplementary Fig. 5a and b **(c)** Control for the generation of stable shTEAD2-

expressing ESC cell lines **(d)** Impact of RASSF1A/YAP, RASSF1A/ β -catenin and

RASSF1A/TEAD1 depletion on core stem cell marker expression in ESC. Tead1

depletion is used as a control. Its depletion leads to increased stem cell marker


expression, verifying its function as a differentiation marker **(e)** Impact of

RASSF1A/TEAD2 depletion on stem cell marker expression in ESC and **(f)** iPSC.


*** $P < 0.001$, of Student's t-test. Error bars indicate s.e.m. Data shown are

representative of at least 3 independent experiments.


a




b




c



d









Supplementary Figure 5. RASSF1A regulates the pluripotency network via the MST/LATS pathway (a) TEAD2 and **(b)** β -catenin CHIP on Tead2 and β -catenin binding sites (BS) on the ESC *Pou5f1/Oct4* promoter in response to the indicated conditions. Intact YAP-TEAD2- β -catenin transcriptional complexes are recruited on the *Pou5f1* distal enhancer upon RASSF1A loss **(c)** YAP CHIP on TEAD2 and TCF binding sites (BS) on the ESC *Pou5f1/Oct4* promoter in response to indicated conditions **(d)** Impact of RASSF1A/MST2 and RASSF1A/LATS1 depletion on core stem cell markers in ESC. The MST/LATS kinase cascade is required for stem cell marker upregulation in response to RASSF1A loss $***P<0.001$, of Student's t-test. Error bars indicate s.e.m. Data shown are representative of at least 3 independent experiments.




Supplementary Figure 6. LATS-dependent YAP phosphorylation in response to RASSF1A (a) Western blots for S127-YAP and Y357-YAP phosphorylation levels. Y357-Yap phosphorylation was used as a control; although present, it does not change in response to RASSF1A. S127-YAP phosphorylation follows RASSF1A levels (b) Negative control for PLA experiment in Fig. 4f and FLAG expression in FLAG-YAP transfected ESC (c) YAP ChIP on *Tead1* gene promoter (d) Western blot controls for Fig 4g (e) Western blot controls for Fig 4h (f) YAP ChIP on differentiation-related gene promoters in response to indicated conditions in the absence of LIF and (g) RNAseq data displaying mRNA expression levels of the respective genes.

a

GEO: Dataset	OCT4 inactivation mESC GDS3599: GSE17439		OCT4 Knockdown mESC GDS1824:GSE4189		H1/H9 differentiation hESC GDS5408: GSE54186			Brg1 depleted 2cell embryo GDS2156:GSE5371	
Transcript	[FOLD]	Sig.	Transformed count	Sig	[FOLD] H1 H9		Sig.	[FOLD]	Sig.
Rassf1	1.56	0.01	UP	0.000002	1.23	1.49	0.037	1.44	0.045
Gata1	1.5	0.037	UP	0.035	1.52	2.92	0.034	-	0.022
Cdkn1a	1.91	0.00003	UP	0.000002	1.84	1.25	0.015	3.73	0.02
Mdm2	1.92	0.001	UP	<i>ns</i>		1.73	-	1.7	-
Klf3	1.57	0.03	UP	0.00004	1.93	1.32	0.0009	<i>ND</i>	-
Fbxw7	1.51	0.067	UP	0.01	1.21		-	2.042	0.001
Pou5F1	0.87	-	-	-	0.38	0.47	0.0000006	0.98	-
Nanog	0.39	0.025	-	-	0.51	0.57	0.000008	<i>ND</i>	-



Supplementary Figure 7. RASSF1A regulates the core pluripotency network in the pre-implantation embryo (a) *Oct4* inactivation and knockdown in mESC increases RASSF1 and differentiation-promoting, RASSF1-dependent transcripts (GEO datasets GDS3599:GSE17439 and GDS1824:GSE4189 respectively). Those phenotypes are recapitulated upon differentiation of hESC lines H1 and H9 (GEO dataset GDS5408:GSE54186). Similarly, loss of the RASSF1A suppressor *Brg1* in the 2-cell pre-implantation embryo leads to increase of *Rassf1A* and *Rassf1*-regulated transcripts. Data deriving from GEO dataset GDS2156:GSE5371 (b) Top: Experimental process for *in vivo* experiments. Zygotes (E0.5) were microinjected with various fate determinants and controls and allowed to develop until blastocysts were formed (app. E4.0). Bottom: Experimental control for siRNA-mediated *Rassf1a* KD in the mouse embryo (c) Top: Representative images of embryos microinjected with either non-targeting siRNA (siNT) or siRNAs targeting RASSF5, demonstrating increased core stem cell marker expression upon RASSF5 loss. Bottom: qPCR for *Oct4* and *Nanog* expression from the transfected embryos (d) Percentage of blastocyst forming embryos upon microinjection of the indicated concentration of *Rassf1A* mRNA versus Control (e) Control embryos microinjected with empty vector and non-targeting siRNA (siNT) or sip73 develop normally to the blastocyst stage, n=5. BF: Brightfield channel. Scale: 50 μm , * $P < 0.05$ and *** $P < 0.001$, respectively, of Student's t-test. Error bars indicate s.e.m. Data shown are representative of at least 3 independent experiments.



Supplementary Figure 8. Characterization of iPSC cells (a) Experimental procedure of iPSC and embryoid bodies generation **(b)** Top: Western blot showing induction of HA-RASSF1A in *Rassf1A*^{-/-} MEFs. Bottom: qPCR showing equal expression levels of the SKOM construct in iPSC. Untransfected MEFs were used as negative control **(c)** Representative images of indicated staining in iPSC. *Rassf1A*^{-/-} iPSC express higher levels of core pluripotency markers NANOG and SOX2 than *Rassf1A*^{+/+} counterparts **(d)** Western blotting of YAP immunoprecipitates in *Rassf1A*^{+/+, -/-} and *-/-+HA-RASSF1A* iPSC with the indicated antibodies **(e)** Proteomics analysis for differences in pS127-YAP in RASSF1A-expressing versus non-expressing iPSC. All cells are transfected with a FLAG-YAP1 (human) construct. All mass-spec intensities were normalized to YAP intensities for each sample. See also Supplementary Table 4 **(f)** qPCR for differentiation markers Nestin (ectoderm) and Vimentin (mesoderm-endoderm) from indicated conditions, following LIF withdrawal for 96 h **(g)** qPCR for the differentiation marker Nestin in the indicated conditions, following LIF withdrawal for 96h **(h)** Quantification of round colonies 4 days after LIF withdrawal **(i)** Embryoid bodies (EB) forced to differentiate towards the dendritic cell (DC) lineage upon GM-CSF and rIL-3 treatment. From left to right: *Rassf1A*^{-/-} EBs maintain round iPSC shape; Dendritic cell (DC)-specific cd54 marker expression upon induction of differentiation, assessed via FACS. The bar graphs illustrate cd54-expressing cells in the absence of LPS; LPS used as positive control to activate DCs. The bar graphs illustrate cd11c expressing cells in the presence of LPS **(j)** Example images of iPSC staining with the proliferation marker Ki67 to assess cell cycle exit **(k)** *Rassf1A*^{-/-} MEFs are insensitive to TGFβ-mediated disruption of reprogramming, in contrast to *Rassf1A*^{+/+} MEFs, indicating that *Rassf1A*-mediated regulation of pluripotency may be dominant over induction of mesenchymal-to-epithelial transition (MET). Scale bars: 25-50 μm. **P*<0.05, ***P*<0.01 and ****P*<0.001, respectively, of Student's t-test. Error bars indicate s.e.m. Data shown are representative of at least 3 independent experiments.

Fig 1c




Fig 1g




Fig 3e




Fig 3e





Fig 3f



Supplementary Figure 9. Uncropped scans of blots from indicated figures

Fig 4b




Fig 4d







Fig 4e




Supp Fig 1d




Supp Fig 3e



Supp Fig 3g




Supp Fig 4d




Supplementary Figure 10. Uncropped scans of blots from indicated figures


Supp Fig 4e




Supp Fig 4f




Supp Fig 5d




Supp Fig 6a



Supp Fig 6d



Supp Fig 6e



Supplementary Figure 11. Uncropped scans of blots from indicated figures